{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T07:13:00Z","timestamp":1793776380203,"version":"4.6.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.tjpad.2025.100446","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T13:57:53Z","timestamp":1764597473000},"page":"100446","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Donanemab in early symptomatic Alzheimer\u2019s disease: results from the TRAILBLAZER-ALZ 2 long-term extension"],"prefix":"10.1016","volume":"13","author":[{"given":"Jennifer A.","family":"Zimmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5090-7886","authenticated-orcid":false,"given":"John R.","family":"Sims","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia D.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emel Serap Monkul","family":"Nery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alette M.","family":"Wessels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Tronchin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8551-434X","authenticated-orcid":false,"given":"Shoichiro","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Lau","family":"Raket","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2679-3921","authenticated-orcid":false,"given":"Scott W.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Sapin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Ange","family":"Paget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivelina","family":"Gueorguieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Ardayfio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashna","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn A.","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandy R.","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Mintun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tjpad.2025.100446_bib0001","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer's disease: the amyloid cascade hypothesis","volume":"256","author":"Hardy","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.tjpad.2025.100446_bib0002","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.tjpad.2025.100446_bib0003","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjpad.2025.100446_bib0004","article-title":"Elecsys total-tau CSF","year":"2023","journal-title":"Method sheet"},{"key":"10.1016\/j.tjpad.2025.100446_bib0005","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70491","article-title":"Donanemab exposure-response in early symptomatic Alzheimer's disease","volume":"21","author":"Gueorguieva","year":"2025","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100446_bib0006","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1590\/1980-57642015DN92000009","article-title":"Charchat-Fichman H. The most frequently used tests for assessing executive functions in aging","volume":"9","author":"Faria","year":"2015","journal-title":"Dement Neuropsychol"},{"key":"10.1016\/j.tjpad.2025.100446_bib0007","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1093\/ejcts\/ezy167","article-title":"Statistical primer: propensity score matching and its alternatives","volume":"53","author":"Benedetto","year":"2018","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.tjpad.2025.100446_bib0008","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1093\/aje\/kwq198","article-title":"Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution\u2013a simulation study","volume":"172","author":"St\u00fcrmer","year":"2010","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.tjpad.2025.100446_bib0009","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.jalz.2018.06.1353","article-title":"Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale","volume":"14","author":"Navitsky","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100446_bib0010","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1001\/jamaneurol.2025.2218","article-title":"Concordance between amyloid-PET quantification and real-world visual reads","volume":"82","author":"Zeltzer","year":"2025","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.tjpad.2025.100446_bib0011","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1001\/jamaneurol.2022.2793","article-title":"Association of amyloid reduction after donanemab treatment with tau pathology and clinical outcomes: the TRAILBLAZER-ALZ randomized clinical trial","volume":"79","author":"Shcherbinin","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.tjpad.2025.100446_bib0012","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/cpt.2875","article-title":"Donanemab population pharmacokinetics, amyloid plaque reduction, and safety in participants with Alzheimer's disease","volume":"113","author":"Gueorguieva","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.tjpad.2025.100446_bib0013","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jamaneurol.2025.0065","article-title":"Amyloid-related imaging abnormalities with donanemab in early symptomatic Alzheimer disease: secondary analysis of the TRAILBLAZER-ALZ and ALZ 2 randomized clinical trials","volume":"82","author":"Zimmer","year":"2025","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.tjpad.2025.100446_bib0014","doi-asserted-by":"crossref","first-page":"e1347","DOI":"10.1212\/WNL.0000000000011524","article-title":"Alzheimer's disease neuroimaging initiative. Temporal dynamics of \u03b2-amyloid accumulation in aging and Alzheimer disease","volume":"96","author":"Jagust","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.tjpad.2025.100446_bib0015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10928-024-09959-y","article-title":"Quantifying natural amyloid plaque accumulation in the continuum of Alzheimer's disease using ADNI","volume":"52","author":"Elhefnawy","year":"2025","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.tjpad.2025.100446_bib0016","doi-asserted-by":"crossref","first-page":"9","DOI":"10.14283\/jpad.2022.102","article-title":"Establishing clinically meaningful change on outcome assessments frequently used in trials of mild cognitive impairment due to Alzheimer's disease","volume":"10","author":"Lansdall","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2025.100446_bib0017","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13195-020-00659-6","article-title":"Assessing what matters most to patients with or at risk for Alzheimer's and care partners: a qualitative study evaluating symptoms, impacts, and outcomes","volume":"12","author":"DiBenedetti","year":"2020","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.tjpad.2025.100446_bib0018","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40120-023-00445-0","article-title":"Assessing what matters to people affected by Alzheimer's disease: a quantitative analysis","volume":"12","author":"Hauber","year":"2023","journal-title":"Neurol Ther"},{"key":"10.1016\/j.tjpad.2025.100446_bib0019","article-title":"Time-based measures for quantifying disease modification in Alzheimer\u2019s disease","volume":"20","author":"Raket","year":"2025","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100446_bib0020","doi-asserted-by":"crossref","first-page":"6374","DOI":"10.1002\/alz.14134","article-title":"Scenarios for the long-term efficacy of amyloid-targeting therapies in the context of the natural history of Alzheimer's disease","volume":"20","author":"Raket","year":"2024","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100446_bib0021","article-title":"Donanemab immunogenicity in participants with early symptomatic Alzheimer's disease","volume":"11","author":"Mullins","year":"2025","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100446_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100266","article-title":"The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema\/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6","author":"Wang","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2025.100446_bib0023","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1002\/alz.13700","article-title":"How donanemab data address the coverage with evidence development questions","volume":"20","author":"Klein","year":"2024","journal-title":"Alzheimers Dement"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580725003875?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580725003875?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T20:25:38Z","timestamp":1776198338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580725003875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2274580725003875"],"URL":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100446","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Donanemab in early symptomatic Alzheimer\u2019s disease: results from the TRAILBLAZER-ALZ 2 long-term extension","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100446","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Eli Lilly and Company. Published by Elsevier Masson SAS on behalf of SERDI Publisher.","name":"copyright","label":"Copyright"}],"article-number":"100446"}}